Bone Marrow Transplant Success Rates for Thalassemia in China: Overall Survival, Thalassemia-Free Survival, and Donor-Type Outcomes Data for International Patients, Families, and Physicians

Why There Is No Single “Success Rate” for Thalassemia Transplant

When families search for a thalassemia transplant success rate, they usually find a single percentage cited without context. In practice, transplant centers and researchers track several distinct outcome measures, and a treatment can look very different depending on which one is reported:

A patient can be alive (counted in OS) but not thalassemia-free, if graft failure led to a return to transfusions. This is why a single headline number is rarely enough to compare studies meaningfully, and why the breakdown below reports each measure separately rather than collapsing them into one figure.

The Largest Published Donor-Comparison Trial: 823 Patients Across 16 Centers in China

Most published thalassemia transplant series are single-center and focus on one donor type. A 2026 multi-center trial changes that picture: it prospectively followed 823 patients with transfusion-dependent thalassemia (787 beta-thalassemia, 36 alpha-thalassemia) transplanted between 2019 and 2023 across 16 transplant centers in China — 331 using a matched sibling donor and 492 using an alternative donor (352 matched unrelated, 140 haploidentical).

All patients received the same conditioning regimen (busulfan, cyclophosphamide, fludarabine, and anti-thymocyte globulin), which the study authors credit for an unusually low overall graft failure rate of 0.5% — notably lower than the 6–22% range reported in earlier alternative-donor series. The trial reports outcomes separately by donor type, which is what makes it useful for families trying to understand how donor choice specifically affects the numbers, rather than relying on outcomes pooled across very different patient groups.

This trial is also directly relevant to families evaluating haploidentical transplant as an option, since 140 of its 823 patients used a parent or other family donor rather than a matched sibling or registry match.

Success Rates by Donor Type: The Full Breakdown

The table below reports the trial's 2-year outcomes for each donor type. Overall survival and event-free survival were closest between matched sibling and haploidentical donors; the more noticeable gap between donor types shows up in GVHD-free, relapse-free survival (GRFS) — a stricter composite measure that also captures graft-versus-host disease burden.

OS and EFS for matched unrelated donors were statistically lower than matched sibling (p<0.05); OS and EFS for haploidentical donors were not statistically different from matched sibling (p>0.05). Trial-wide (not broken down by donor type in the published results): transplant-related mortality 4.4%; graft failure 0.5%.

A second, separate evidence base focuses specifically on pediatric haploidentical transplant: a systematic review and meta-analysis pooling 10 studies reported overall survival of 92.4%, thalassemia-free survival of 84.5%, graft failure of 8.1%, and transplant-related mortality of 7.4%, with infection identified as the leading cause of transplant-related death. Acute GVHD occurred in a pooled 29.6% of patients (22.3% grade 2–4, 9.1% grade 3–4).

These two evidence bases are not directly comparable — one is a single large prospective trial with a uniform conditioning protocol, the other pools multiple smaller studies with varying protocols and follow-up periods. The gap between the 0.5% and 8.1% graft failure figures illustrates why conditioning regimen, CD34+ cell dose, and prior transfusion burden matter as much as donor type itself, and why comparing raw percentages across studies without checking study design can be misleading.

What Else Affects Success Rates Besides Donor Type?

Donor type is only one variable. Across nearly all published thalassemia transplant series, the degree of pre-transplant organ damage — particularly liver fibrosis and iron overload accumulated from years of transfusion — is one of the strongest predictors of outcome, independent of which donor is used. Risk classification systems developed from early transplant experience (commonly called Pesaro or Lucarelli risk classes) group patients by liver size, portal fibrosis, and chelation adequacy, and patients transplanted before significant organ damage accumulates consistently show better outcomes across studies.

Patient age at transplant, prior alloimmunization from transfusions, and overall center experience with thalassemia-specific conditioning protocols also influence results. The full timing framework — including how organ-damage risk staging is assessed and why timing is often as important as the transplant decision itself — is covered in our guide to when bone marrow transplant is the right option for thalassemia major.

Why China's Transplant Data Is Particularly Relevant Here

Thalassemia has notable prevalence in parts of southern China, and Chinese pediatric transplant centers have accumulated substantial case volume as a result — the 823-patient trial referenced throughout this article was conducted entirely across 16 Chinese centers, making it one of the largest published single-condition, multi-donor-type transplant series for thalassemia anywhere.

This is also part of a broader pattern: China's CCBMTR pediatric registry separately documents haploidentical donor use across tens of thousands of pediatric transplants nationally, spanning thalassemia, aplastic anemia, and other conditions covered in ChinaMed Waypoint's rare blood disorders resources. For international families, this gives access to a comparatively large, recent, and donor-type-specific published evidence base — which matters when the question is not just “does transplant work,” but “how does the specific donor available to my family compare.”

Suitability for any individual patient still depends on clinical review of their specific records, not on which country published the largest dataset.

How to Read These Numbers for an Individual Case

Population-level outcome data describe what happened, on average, to groups of patients who may differ from any one patient in age, organ status, transfusion history, or the specific conditioning protocol used at their center. Before treating any published percentage as directly applicable, it is worth asking a transplant team:

A structured case review can apply this kind of published data to a specific patient's records — rather than leaving a family to compare percentages from different studies on their own.

Supportive Care Alongside Transplant

The outcome figures above describe the transplant itself, but recovery is also shaped by supportive care during conditioning, engraftment, and the months that follow. At Chinese hematology centers, supportive care alongside standard transplant treatment may include integrative approaches such as acupuncture and Traditional Chinese Medicine for fatigue, sleep, and appetite support — used alongside, and never as a replacement for, transfusion, chelation, or transplant conditioning.

See the supportive care and Traditional Chinese Medicine resources for more on what integrative supportive care during hematology treatment in China may involve.